AstraZeneca PLC

AstraZeneca PLC is a Swedish-British multinational pharmaceutical and biotechnology company with its global headquarters located at the Cambridge Biomedical Campus in Cambridge, UK. The company's mission is "to push the boundaries of science to deliver life-changing medicines," reflecting a commitment to pioneering scientific discovery and patient-centric innovation.

AstraZeneca focuses on the discovery, development, manufacture, and commercialization of prescription medicines across several key therapeutic areas. These include Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Diseases. Its product portfolio features significant drugs such as Tagrisso, Imfinzi, Lynparza, and Enhertu in oncology, Farxiga and Brilinta for CVRM, and Ultomiris and Soliris for rare diseases.

Led by CEO Pascal Soriot, AstraZeneca is a prominent global biopharmaceutical company. Recent developments include a £300 million investment in the UK, signaling renewed confidence following a favorable drug pricing agreement. The company reported strong Q1 2026 earnings, surpassing estimates, largely driven by robust oncology sales, though a breast cancer candidate drug recently faced a setback with an FDA advisory committee vote. AstraZeneca also emphasizes sustainability, with initiatives like its Ambition Zero Carbon program.